Key Takeaways
- Promising Alternative: Inhaled Insulin (Afrezza) when combined with degludec insulin (Tresiba®) showed potential as an effective alternative to traditional insulin delivery methods for people with Type 1 diabetes (T1D).
- Improved Glycemic Control: Participants using the inhaled insulin regimen experienced significant improvements in HbA1c levels, with some achieving the target HbA1c goal of less than 7%.
- Patient Satisfaction: Over half of the study participants expressed a desire to continue using inhaled insulin after the study, indicating a positive reception to this novel treatment approach.
We are thrilled to announce that the Connected in Motion (CIM) team is attending the 84th Scientific Sessions of the American Diabetes Association (ADA) this year in Orlando, Florida. This annual event is a cornerstone in the global diabetes community, bringing together leading researchers, clinicians, and innovators to share the latest advancements in diabetes care.
Stay tuned as we share highlights and key takeaways from the sessions, continuing our commitment to enhancing the lives of those living with type 1 diabetes.
At the ADA Scientific Sessions, the INHALE-3 study on inhaled insulin (Afrezza) combined with degludec insulin (Tresiba®) was a significant highlight. (Learn more about the many types of insulins, here!)The findings presented showcased an alternative insulin solution that could enhance diabetes management for adults with Type 1 diabetes (T1D).
Study Overview
The INHALE-3 trial was a randomized study that took place over 17 weeks across 19 centres in the U.S. It involved 123 adults with T1D, divided into two groups: one receiving the inhaled insulin plus degludec insulin regimen, and the other continuing their usual care, which included either automated insulin delivery systems or multiple daily injections.
Key Findings
- HbA1c Improvement: Participants using the inhaled insulin regimen saw more significant improvements in their HbA1c levels compared to those on usual care. Notably, 21% of those on inhaled insulin had an HbA1c improvement of greater than 0.5%, while only 5% of those with standard care saw similar results.
- Achieving HbA1c Goals: Among participants with a starting HbA1c level of 7% or higher, 21% of those on inhaled insulin achieved the target HbA1c goal of less than 7%. In contrast, none of the participants receiving standard care reached this goal.
- Switch from Automated Insulin Delivery: Nineteen percent of participants who switched from automated insulin delivery to inhaled insulin plus degludec achieved an HbA1c improvement greater than 0.5%.
Despite these positive findings, it’s important to note that this treatment method was not suitable for everyone. Twenty-six percent of the patients in the inhaled insulin group experienced a worsening of HbA1c greater than 0.5%, compared to just 3% with standard care.
Reception
Significantly, over half of the study participants expressed a desire to continue using inhaled insulin after the study, highlighting the potential for improved satisfaction and adherence with this novel treatment.
Expert Insight
Dr. Irl B. Hirsch from the University of Washington, the lead author of the study, emphasized the impact of these findings: “The INHALE-3 study’s findings will impact diabetes management by providing healthcare providers and patients with an alternative insulin delivery method. These results will assist in better informing clinical decisions and tailoring treatment plans to individual patient needs, potentially improving adherence, patient satisfaction, and overall outcomes.”
Looking Ahead
Building on the promising results of INHALE-3, future research will explore the impact of inhaled insulin on a broader patient population, including pediatrics and pregnancy.
Stay tuned for more updates from the ADA Scientific Sessions as we continue to bring you the latest developments in diabetes management.
